Part 1 of the study determines the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving specific first line treatments for Stage 3 or metastatic non-small cell lung cancer. Part 2 compares the efficacy of inupadenant to placebo when both are combined with carboplatin and pemetrexed for patients that progressed after receiving the same first line treatments for Stage 3 or metastatic non-small cell lung cancer.
3 Primary · 10 Secondary · Reporting Duration: From randomization to death due to any cause, assessed up to 24 months.
192 Total Participants · 3 Treatment Groups
Primary Treatment: Part 2, active treatment · Has Placebo Group · Phase 2
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: